TOP 100 MEDICAL SITES
| |||
|
| |||
| |||
|
| |||
| Elan CEO to Step Down in 2012 Irish biotech company Elan, facing long-running shareholder dissatisfaction over company management, said Chief Executive Kelly Martin will step down in 2012. online.wsj.com |
J&J Plant Closing to Continue Johnson & Johnson said it won't reopen a Pennsylvania production plant that makes children's medicines before the end of this year. online.wsj.com |
Lilly's Enzyme Inhibitor for Alzheimer's: Worse Than Nothing Derek Lowe submits: Well, well, well. We finally have solid clinical data from a large trial of a gamma-secretase inhibitor for Alzheimer's disease. And it doesn't work. Background, for those outside the field: a hallmark of Alzheimer's is the appearance of plaques in the brain. These are insoluble clumps of a protein called amyloid-beta, surrounded by dead and dying neurons. This amyloid is split off (for some reason) from the middle of a larger precursor protein (APP), and there are two enzymes that make the cuts to release it: gamma-secretase and beta-secretase. Shutting down one or both of those has long been seen as the most direct route to keeping amyloid from accumulating, and compounds that do this have been sought for at least twenty years now.Complete Story » seekingalpha.com |
ImmunoGen Suffers From the Second Lethal Virus Prohost Biotech submits:Two lethal viruses plague general investors. The euphoria virus infects investors when the market stages sustained rallies. This virus makes investors buy and buy until the balloon becomes overstretched and eventually bursts. The fear virus causes hysteria in susceptible investors when their stocks go south and rush them to sell at ridiculously low prices. The fear virus also provokes vulnerable investors to immediately dispose of their stocks at the hint of unfavorable news, whether or not the negative news is indicative of weakness in the firms’ fundamentals. Healthy, rational investors usually take advantage to accumulate the battered stocks of firms with strong fundamentals at the new bargain price that results from sell-offs by the fearful. A case in point: Immunogen (IMGN)Complete Story » seekingalpha.com |
Trius to Participate in the Piper Jaffray Health Care Conference [GlobeNewswire] - SAN DIEGO -- Trius Therapeutics, Inc. announced today that Jeffrey Stein, Ph.D., President and Chief Executive Officer of Trius Therapeutics, will participate in an informal "fireside chat" with research analyst Edward Tenthoff at Piper Jaffray's 22nd Annual Health Care Conference. us.rd.yahoo.com |